7.99
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt AUPH?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$8.00
Offen:
$7.96
24-Stunden-Volumen:
873.25K
Relative Volume:
0.66
Marktkapitalisierung:
$1.08B
Einnahmen:
$175.51M
Nettoeinkommen (Verlust:
$-78.02M
KGV:
-15.08
EPS:
-0.53
Netto-Cashflow:
$-34.18M
1W Leistung:
+0.13%
1M Leistung:
-2.68%
6M Leistung:
-8.37%
1J Leistung:
+51.61%
Aurinia Pharmaceuticals Inc Stock (AUPH) Company Profile
Firmenname
Aurinia Pharmaceuticals Inc
Sektor
Branche
Telefon
250-744-2487
Adresse
#140, 14315 - 118 AVENUE, EDMONTON, BC
Vergleichen Sie AUPH mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
AUPH
Aurinia Pharmaceuticals Inc
|
7.99 | 1.08B | 175.51M | -78.02M | -34.18M | -0.53 |
![]()
ONC
Beone Medicines Ltd Adr
|
258.27 | 26.01B | 3.81B | -644.79M | -669.77M | -6.24 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
445.85 | 114.30B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
AKTX
Akari Therapeutics Plc Adr
|
1.3499 | 41.83M | 0 | 0 | 0 | 0.00 |
![]()
VRNA
Verona Pharma Plc Adr
|
83.98 | 6.29B | 0 | -153.72M | -103.81M | -2.00 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
484.93 | 63.90B | 14.09B | 4.50B | 2.96B | 39.28 |
Aurinia Pharmaceuticals Inc Stock (AUPH) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2022-11-04 | Herabstufung | Oppenheimer | Outperform → Perform |
2022-05-05 | Fortgesetzt | Cantor Fitzgerald | Overweight |
2021-12-10 | Hochstufung | Oppenheimer | Perform → Outperform |
2021-10-28 | Herabstufung | Oppenheimer | Outperform → Perform |
2021-01-25 | Bestätigt | H.C. Wainwright | Buy |
2020-11-03 | Bestätigt | H.C. Wainwright | Buy |
2020-06-17 | Eingeleitet | BTIG Research | Buy |
2020-05-05 | Eingeleitet | Cowen | Outperform |
2020-01-10 | Eingeleitet | Jefferies | Buy |
2019-12-16 | Bestätigt | H.C. Wainwright | Buy |
2018-03-16 | Bestätigt | Cantor Fitzgerald | Overweight |
2018-02-08 | Eingeleitet | RBC Capital Mkts | Outperform |
2017-10-30 | Bestätigt | H.C. Wainwright | Buy |
2017-05-18 | Bestätigt | H.C. Wainwright | Buy |
2017-04-11 | Eingeleitet | Cantor Fitzgerald | Overweight |
2017-03-22 | Bestätigt | FBR & Co. | Outperform |
2016-12-30 | Bestätigt | H.C. Wainwright | Buy |
2016-08-17 | Bestätigt | H.C. Wainwright | Buy |
2016-06-30 | Eingeleitet | H.C. Wainwright | Buy |
2015-05-08 | Eingeleitet | MLV & Co | Buy |
Alle ansehen
Aurinia Pharmaceuticals Inc Aktie (AUPH) Neueste Nachrichten
The Gross Law Firm Announces Class Actions on Behalf of Shareholders of AUPH, IRNT and RSKD - ACCESS Newswire
Is the Options Market Predicting a Spike in Aurinia Pharmaceuticals (AUPH) Stock? - MSN
BNP Paribas Financial Markets Sells 14,003 Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) - Defense World
Is The Options Market Predicting A Spike In Aurinia Pharmaceuticals (AUPH) Stock? - Barchart.com
(AUPH) Technical Data - news.stocktradersdaily.com
Aurinia Pharmaceuticals (AUPH) Reports Positive Lupkinis Trial Results | AUPH Stock News - GuruFocus
Aurinia Pharmaceuticals’ LUPKYNIS Shows Promising Results in Lupus Nephritis Study - TipRanks
Aurinia Pharmaceuticals' (NASDAQ:AUPH) Strong Earnings Are Of Good Quality - simplywall.st
Aurinia Pharmaceuticals' (NASDAQ:AUPH) Performance Is Even Better Than Its Earnings Suggest - Yahoo Finance
Aurinia Pharmaceuticals Inc. Just Recorded A 60% EPS Beat: Here's What Analysts Are Forecasting Next - Yahoo Finance
Aurinia Pharmaceuticals Approves New Equity Incentive Plan - TipRanks
Aurinia Pharmaceuticals Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year - simplywall.st
Aurinia Pharmaceuticals First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Transcript : Aurinia Pharmaceuticals Inc.Shareholder/Analyst Call - marketscreener.com
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Q1 2025 Earnings Call Transcript - MSN
Aurinia Pharmaceuticals Financial Update and Strategic Growth Plans - Zenopa
Aurinia Pharmaceuticals (AUPH) Reports Strong Q1 Earnings Beat - GuruFocus
Aurinia outlines $250M–$260M 2025 revenue target as LUPKYNIS sales climb 25% and operational efficiency improves - MSN
Decoding Aurinia Pharmaceuticals Inc (AUPH): A Strategic SWOT In - GuruFocus
Aurinia Pharmaceuticals Reports Strong Q1 2025 Earnings - TipRanks
Document - SEC.gov
Aurinia Pharmaceuticals Q1 2025 Earnings: Strong Growth Amid Challenges - TipRanks
Aurinia: Q1 Earnings Snapshot - MySA
Aurinia Pharmaceuticals Q1 2025 Earnings Call Transcript - MarketBeat
Aurinia Pharma Swings Into Profit As Q1 Sales Jumps 24%, Sticks To Guidance - Benzinga
Leerink maintains Aurinia stock Outperform with $10 target - Investing.com
Aurinia Stock Rallies On Upbeat Q1 Earnings, CEO Expects Strong Performance in 2025: Retail Sentiment Brightens - Investing.com India
AUPH Reports Q1 Revenue Exceeding Expectations with Strong Outlo - GuruFocus
Aurinia Pharmaceuticals (AUPH) Surpasses Q1 Earnings and Revenue Estimates - Yahoo Finance
Aurinia Pharmaceuticals' Q1 Swings to Profit, Revenue Rises; Reiterates 2025 Revenue Guidance - marketscreener.com
Aurinia Pharmaceuticals Inc. SEC 10-Q Report - TradingView
Aurinia Pharmaceuticals Inc. Reiterates Guidance for the Full Year 2025 - marketscreener.com
Aurinia Pharmaceuticals Reports Strong First Quarter 2025 Financial Results - TipRanks
Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2025 - Business Wire
Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) CEO Will Probably Find It Hard To See A Huge Raise This Year - simplywall.st
How the (AUPH) price action is used to our Advantage - news.stocktradersdaily.com
Aurinia Pharmaceuticals to Release First Quarter 2025 Financial and Operational Results on May 12, 2025 - BioSpace
Glass Lewis Supports Aurinia’s Proposals for 2025 AGM - TipRanks
ISS Endorses Aurinia’s Proposals for 2025 Annual Meeting - TipRanks
Glass Lewis Recommends That Aurinia Shareholders Vote “FOR” All Proposals at 2025 Annual General Meeting - The Globe and Mail
ISS Recommends That Aurinia Shareholders Vote “FOR” All Proposals at 2025 Annual General Meeting - BioSpace
Aurinia Pharmaceuticals (AUPH) Gains Support from ISS for Board - GuruFocus
Aurinia Pharmaceuticals Inc expected to post earnings of 10 cents a shareEarnings Preview - TradingView
Finanzdaten der Aurinia Pharmaceuticals Inc-Aktie (AUPH)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):